IONS
HEALTHCAREIonis Pharmaceuticals Inc
AI Insight
What's Moving IONS Today?
No stock-specific AI insight has been generated for IONS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$38.99$86.74
$75.99
Fundamentals
Market Cap$12.4B
P/E Ratio—
EPS$-2.01
Dividend Yield—
Dividend / Share—
ROE-67.6%
Profit Margin-30.9%
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding165.3M
IONS News
25 articles- How Kardigan spun deal leftovers into a $400M IPOBiopharmadive·Jun 23, 2026
- Is lonis Pharmaceuticals, Inc. (IONS) Among the Best Genomics Stocks to Buy According to Analysts?Yahoo Finance·Jun 16, 2026
- Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?Yahoo Finance·Jun 15, 2026
- Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of DirectorsYahoo Finance·Jun 8, 2026
- Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline UpdatesYahoo Finance·Jun 6, 2026
- Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congressesYahoo Finance·Jun 4, 2026
- This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First QuarterMotley Fool·May 31, 2026
- Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?Yahoo Finance·May 29, 2026
- GSK’s hepatitis B drug touts functional curative potential in double Phase III winClinicaltrialsarena·May 29, 2026
- Why The Story Around Ionis Pharmaceuticals (IONS) Is Shifting After Fresh Analyst Targets And GuidanceYahoo Finance·May 29, 2026
- JPMorgan says large-cap biotech is back as profits and pipelines fuel upsideYahoo Finance·May 28, 2026
- Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis BYahoo Finance·May 28, 2026
- Tryngolza shows efficacy in severe hypertriglyceridemia as approval verdicts loomClinicaltrialsarena·May 27, 2026
- [Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·May 26, 2026
- Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 ReadoutsMarketbeat·May 26, 2026
- Citi Names 2 Biotech Stocks ‘Top Picks’ for 2026Yahoo Finance·May 24, 2026
- Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk247 Wall St·May 19, 2026
- StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst callsYahoo Finance·May 19, 2026
- Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at ConferenceMarketbeat·May 18, 2026
- Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.Yahoo Finance·May 14, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightGlobeNewswire Inc.·Apr 22, 2026
- Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic EncephalopathyGlobeNewswire Inc.·Apr 6, 2026
- Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger MarketBenzinga·Mar 26, 2026
- When Insider Selling Is a Good Thing: 2 Stocks to WatchInvesting.com·Mar 24, 2026
All 25 articles loaded
Price Data
Open$75.89
Previous Close$75.89
Day High$77.31
Day Low$75.77
52 Week High$86.74
52 Week Low$38.99
52-Week Range
$38.99$86.74
$75.99
Fundamentals
Market Cap$12.4B
P/E Ratio—
EPS$-2.01
Dividend Yield—
Dividend / Share—
ROE-67.6%
Profit Margin-30.9%
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding165.3M
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—